Rapid screening for potentially relevant polymorphisms in the human fatty acid amide hydrolase gene using Pyrosequencing™

Prostaglandins and Other Lipid Mediators

Volumn 84, Issue 3-4, 2007, Pages 128-137

  Doehring, Alexandra ^a   Geisslinger, Gerd ^a   Lötsch, Jörn ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

FAAH; Pyrosequencing assays; Single nucleotide polymorphism (SNP)

Indexed keywords

FATTY ACID AMIDASE;

ALLELE; ANALYTIC METHOD; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA DETERMINATION; DNA POLYMORPHISM; FATTY ACID AMIDE HYDROLASE GENE; GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC SCREENING; GENOTYPE; HETEROZYGOSITY; HIGH THROUGHPUT SCREENING; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; NORMAL HUMAN; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; AMIDOHYDROLASES; BASE SEQUENCE; EXONS; HAPLOTYPES; HETEROZYGOTE; HOMOZYGOTE; HUMANS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; TIME FACTORS;

EID: 35648961270     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2007.06.001     Document Type: Article

References (46)

1. McKinney M.K., and Cravatt B.F. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 74 (2005) 411-432
2. Di Marzo V. Endocannabinoids in the new millennium. Prostag Leukot Essent Fatty Acids 66 (2002) 91-92
3. Fowler C.J. The cannabinoid system and its pharmacological manipulation-a review, with emphasis upon the uptake and hydrolysis of anandamide. Fundam Clin Pharmacol 20 (2006) 549-562
4. Lambert D.M., and Fowler C.J. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem 48 (2005) 5059-5087
5. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
6. Pertwee R.G. Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6 (1999) 635-664
7. Smita K., Sushil Kumar V., and Premendran J.S. Anandamide: an update. Fundam Clin Pharmacol 21 (2007) 1-8
8. Crawley J.N., Corwin R.L., Robinson J.K., Felder C.C., Devane W.A., and Axelrod J. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol Biochem Behav 46 (1993) 967-972
9. Fride E., and Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 231 (1993) 313-314
10. Smith P.B., Compton D.R., Welch S.P., Razdan R.K., Mechoulam R., and Martin B.R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 270 (1994) 219-227
11. Willoughby K.A., Moore S.F., Martin B.R., and Ellis E.F. The biodisposition and metabolism of anandamide in mice. J Pharmacol Exp Ther 282 (1997) 243-247
12. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., and Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384 (1996) 83-87
13. Deutsch D.G., and Chin S.A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46 (1993) 791-796
14. Giang D.K., and Cravatt B.F. Molecular characterization of human and mouse fatty acid amide hydrolases. Proc Natl Acad Sci USA 94 (1997) 2238-2242
15. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98 (2001) 9371-9376
16. Cravatt B.F., Saghatelian A., Hawkins E.G., Clement A.B., Bracey M.H., and Lichtman A.H. Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc Natl Acad Sci USA 101 (2004) 10821-10826
17. Lichtman A.H., Shelton C.C., Advani T., and Cravatt B.F. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109 (2004) 319-327
18. Fegley D., Gaetani S., Duranti A., Tontini A., Mor M., Tarzia G., et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313 (2005) 352-358
19. Jhaveri M.D., Richardson D., Kendall D.A., Barrett D.A., and Chapman V. Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci 26 (2006) 13318-13327
20. Di Marzo V. Biosynthesis and inactivation of endocannabinoids: relevance to their proposed role as neuromodulators. Life Sci 65 (1999) 645-655
21. Kurahashi Y., Ueda N., Suzuki H., Suzuki M., and Yamamoto S. Reversible hydrolysis and synthesis of anandamide demonstrated by recombinant rat fatty-acid amide hydrolase. Biochem Biophys Res Commun 237 (1997) 512-515
22. den Dunnen J.T., and Antonarakis S.E. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 15 (2000) 7-12
23. Chiang K.P., Gerber A.L., Sipe J.C., and Cravatt B.F. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet 13 (2004) 2113-2119
24. Sipe J.C., Waalen J., Gerber A., and Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes (Lond) 29 (2005) 755-759
25. Sipe J.C., Chiang K., Gerber A.L., Beutler E., and Cravatt B.F. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci USA 99 (2002) 8394-8399
26. Flanagan J.M., Gerber A.L., Cadet J.L., Beutler E., and Sipe J.C. The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. Hum Genet 120 (2006) 581-588
27. Tyndale R.F., Payne J.I., Gerber A.L., and Sipe J.C. The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: Studies of drug use and dependence in Caucasians. Am J Med Genet B Neuropsychiatr Genet (2007)
28. Kim H., Mittal D.P., Iadarola M.J., and Dionne R.A. Genetic predictors for acute experimental cold and heat pain sensitivity in humans. J Med Genet 43 (2006) e40
29. Nyren P., and Lundin A. Enzymatic method for continuous monitoring of inorganic pyrophosphate synthesis. Anal Biochem 151 (1985) 504-509
30. Ronaghi M., Uhlen M., and Nyren P. A sequencing method based on real-time pyrophosphate. Science 281 (1998) 363 365
31. Ronaghi M., Karamohamed S., Pettersson B., Uhlen M., and Nyren P. Real-time DNA sequencing using detection of pyrophosphate release. Anal Biochem 242 (1996) 84-89
32. Hardy G.H. Mendelian proportions in a mixed population. Science 28 (1908) 49-50
33. Lewontin R.C. The interaction of selection and linkage. I. General considerations; heterotic models. Genetics 49 (1964) 49-67
34. Gaut B.S., and Long A.D. The lowdown on linkage disequilibrium. Plant Cell 15 (2003) 1502-1506
35. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263-265
36. Qin Z.S., Niu T., and Liu J.S. Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms. Am J Hum Genet 71 (2002) 1242-1247
37. Gabriel S.B., Schaffner S.F., Nguyen H., Moore J.M., Roy J., Blumenstiel B., et al. The structure of haplotype blocks in the human genome. Science 296 (2002) 2225-2229
38. Solovieva S., Leino-Arjas P., Saarela J., Luoma K., Raininko R., and Riihimaki H. Possible association of interleukin 1 gene locus polymorphisms with low back pain. Pain 109 (2004) 8-19
39. Lee Y.S., Kim H., Wu T.X., Wang X.M., and Dionne R.A. Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs. Clin Pharmacol Ther 79 (2006) 407-418
40. Skarke C., Reus M., Schmidt R., Grundei I., Schuss P., Geisslinger G., et al. The cyclooxygenase 2 genetic variant -765G > C does not modulate the effects of celecoxib on prostaglandin E2 production. Clin Pharmacol Ther 80 (2006) 621-632
41. Halushka M.K., Walker L.P., and Halushka P.V. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 73 (2003) 122-130
42. Wei B.Q., Mikkelsen T.S., McKinney M.K., Lander E.S., and Cravatt B.F. A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem 281 (2006) 36569-36578
43. Sun Y.X., Tsuboi K., Zhao L.Y., Okamoto Y., Lambert D.M., and Ueda N. Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages. Biochim Biophys Acta 1736 (2005) 211-220
44. Ueda N., Yamamoto K., Yamamoto S., Tokunaga T., Shirakawa E., Shinkai H., et al. Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist. Biochim Biophys Acta 1254 (1995) 127-134
45. Kozak K.R., Crews B.C., Morrow J.D., Wang L.H., Ma Y.H., Weinander R., et al. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 277 (2002) 44877-44885
46. Mulder A.M., and Cravatt B.F. Endocannabinoid metabolism in the absence of fatty acid amide hydrolase (FAAH): discovery of phosphorylcholine derivatives of N-acyl ethanolamines. Biochemistry 45 (2006) 11267-11277